John Glenn F.'s most recent trade in Iradimed Corp was a trade of 14,468 Common Stock done at an average price of $97.3 . Disclosure was reported to the exchange on Dec. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 97.26 per share. | 11 Dec 2025 | 14,468 | 7,894 (0%) | 0% | 97.3 | 1,407,158 | Common Stock |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 1,812 | 9,174 (0%) | 0% | - | Common Stock | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 1,812 | 3,624 | - | - | Restricted Stock Units | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.38 per share. | 11 Dec 2025 | 714 | 8,460 (0%) | 0% | 97.4 | 69,529 | Common Stock |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 98.09 per share. | 11 Dec 2025 | 532 | 7,362 (0%) | 0% | 98.1 | 52,184 | Common Stock |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2025 | 21,008 | 0 | - | - | Performance-based Restricted Stock Units | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2025 | 21,008 | 30,629 (0%) | 0% | - | Common Stock | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2025 | 10,504 | 0 | - | - | Restricted Stock Units | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2025 | 10,504 | 13,004 (0%) | 0% | - | Common Stock | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.57 per share. | 07 Dec 2025 | 8,267 | 22,362 (0%) | 0% | 94.6 | 781,810 | Common Stock |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.57 per share. | 07 Dec 2025 | 3,383 | 9,621 (0%) | 0% | 94.6 | 319,930 | Common Stock |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 84.51 per share. | 10 Nov 2025 | 10,651 | 2,500 (0%) | 0% | 84.5 | 900,162 | Common Stock |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 5,796 | 14,563 (0%) | 0% | - | Common Stock | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 5,796 | 5,796 | - | - | Restricted Stock Units | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.24 per share. | 20 Jun 2025 | 1,412 | 13,151 (0%) | 0% | 58.2 | 82,235 | Common Stock |
| Iradimed Corp | John Glenn F. | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2024 | 5,436 | 40,508 | - | - | Restricted Stock Units | |
| Iradimed Corp | F. Glenn John | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2024 | 5,435 | 23,119 | - | - | Performance-based Restricted Stock Units | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 54.18 per share. | 02 Dec 2024 | 2,500 | 4,383 (0%) | 0% | 54.2 | 135,449 | Common Stock |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2024 | 5,796 | 11,592 | - | - | Restricted Stock Units | |
| Iradimed Corp | Glenn F. John | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 7,180 | 17,684 | - | - | Performance-based Restricted Stock Units | |
| Iradimed Corp | John Glenn F. | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 7,180 | 35,072 | - | - | Restricted Stock Units | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 5,795 | 17,388 | - | - | Restricted Stock Units | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 5,795 | 8,295 (0%) | 0% | - | Common Stock | |
| Iradimed Corp | John F. Glenn | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.88 per share. | 20 Jun 2023 | 1,412 | 6,883 (0%) | 0% | 47.9 | 67,607 | Common Stock |
| Ekso Bionics Holdings Inc | John F. Glenn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.82 per share. | 22 Mar 2022 | 3,462 | 35,130 (0%) | 0% | 2.8 | 9,762 | Common Stock |
| Ekso Bionics Holdings Inc | John F. Glenn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 14,596 | 38,592 (0%) | 0% | 0 | Common Stock |